# A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Source: https://onco.cc/trials/nct07111832/  
OnCo record `nct07111832` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab rezetecan, Adebrelimab and Toripalimab in triple-negative breast cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer is a phase 3 interventional study registered as NCT07111832 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 400 participants planned, started 2025-08-20 and due to reach its primary completion in 2028-03. Interventions recorded: SHR-A1811 for Injection, SHR-1316 Injection, Toripalimab Injection and Paclitaxel for Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07111832
- Phase: 3
- Setting: A Phase III, Multicenter, Randomized, Open-label, Active-controlled Study of SHR-A1811 Plus SHR-1316 Versus Toripalimab Plus Nab-paclitaxel in PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT07111832: https://clinicaltrials.gov/study/NCT07111832

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Toripalimab](https://onco.cc/drugs/toripalimab/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07111832.json